MMRF, Synta Pharmaceuticals to develop multiple myeloma drug
The Multiple Myeloma Research Foundation (MMRF) has entered into a joint collaboration with Synta Pharmaceuticals for the clinical development of ganetespib in patients with multiple myeloma.
In support of the collaboration, MMRF will provide funding of up to $1m for a Phase I trial evaluating ganetespib as a single agent and in combination with the proteasome inhibitor bortezomib as a treatment for relapsed multiple myeloma.
The trial will be conducted through Multiple Myeloma Research Consortium (MMRC), which accelerates development of novel and combination treatments for multiple myeloma, by facilitating collaborative research between industry and academia.
The open-label, multi-centre, Phase 1 trial is designed to evaluate ganetespib, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
The trial is estimated to be initiated in the second half of 2011.
Ganetespib is a second generation Hsp90 inhibitor which is currently being evaluated in 11 Phase II trials, and has demonstrated clinical activity as a monotherapy, along with a favorable safety profile.
Related Insight
Suppliers Directory
FeF Chemicals - Manufacturer and Supplier of Benzalkonium Chloride
FeF Chemicals A/S manufactures and supplies Quaternary Ammonium Compounds (Quats), including Benzalkonium Chloride, for pharmaceutical and personal care products. FeF Chemicals also supplies Insulin for use in cell growth media. FeF Chemicals is a fully owned subsidiary of Novo Nordisk A/S, a Danish healthcare company and world leader in diabetes care.
Contract Research & Services > Contract Research > Suppliers
IQnovate - Contract Medical Affairs Services
The IQnovate Life Science Organization is a contract medical affairs organisation and scientific service provider to the Biopharmaceutical industry. IQnovate also extends a premium advisory service to institutional capital investors on biotech investment strategy.
Contract Research & Services > Contract Research > Suppliers
Avicor - Affinity Chromatography and Chemical Microarray Drug Discovery Services
Avicor provides key technologies for the early phase of drug discovery with chemical microarrays, chemoproteomics and interaction-based HTS.
Contract Research & Services > Contract Research > Suppliers
Toxikon Europe - Preclinical Safety Studies and QC Testing for the Life Science Community
For more than 30 years Toxikon has been a leading contract research organisation (CRO) providing high-quality preclinical safety studies to the life science community.
Contract Research & Services > Contract Research > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Contract Research Intelligence
Heart Hope
Published by Medpace
Contract Research & Services > Contract Research > White Papers
Investigator Responsibilities Revisited by FDA
Published by Norwich Clinical Research Associates
Contract Research & Services > Contract Research > White Papers
Real World Development: Increasing Value for Patients
Published by Kinapse
Contract Research & Services > Contract Research > White Papers
Comprehensive Feasibility Assessments in Eastern Europe - Luxury or Necessity?
Published by Centrical Global Limited
Contract Research & Services > Contract Research > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.